Every S-3 that Vor Biopharma Inc. (VOR) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A S-3 covers the shelf registration that lets an established company sell over time, so if you follow VOR and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full VOR filings page.
Vor Biopharma Inc. (VOR) has filed an automatic shelf registration statement on Form S-3ASR as a well-known seasoned issuer, allowing it to offer from time to time an indeterminate amount of common stock, preferred stock, debt securities, warrants and units, including securities issuable upon conversion or exercise of those instruments. Specific terms, prices and amounts for each takedown will be set in a future prospectus supplement.
Vor Biopharma is a clinical-stage biopharmaceutical company developing telitacicept for autoimmune diseases, with a global Phase 3 trial in generalized myasthenia gravis underway and a global Phase 3 trial in Sjögren’s disease initiated with first patient dosed in March 2026. Net proceeds from any offerings may be used for working capital, capital expenditures, general corporate purposes and potentially for acquisitions or in-licensing of complementary businesses or technologies.
The company qualifies as both an emerging growth company and a smaller reporting company but, based on non-affiliate market value as of June 30, 2026, expects to cease both statuses on December 31, 2026, after which it will be subject to increased disclosure and governance requirements. Vor’s common stock trades on The Nasdaq Global Select Market under the symbol VOR, and the last reported sale price was $24.24 per share on September 3, 2026.
Vor Biopharma Inc. files a preliminary shelf prospectus to register for resale up to 5,338,078 shares of its common stock held by investors from a March 30, 2026 private placement. The shares were issued at $14.05 per share; Vor will receive no proceeds from resales. The registration satisfies contractual registration rights and the company agreed to use reasonable best efforts to have the registration declared effective.
Vor Biopharma Inc. is registering up to 13,876,032 shares of common stock for resale on behalf of investors from a December 18, 2025 private placement. These shares were sold at $10.81 per share for gross proceeds of $150 million, which the company has already received.
The selling stockholders may dispose of their shares over time in public or private transactions, and Vor Biopharma will not receive any proceeds from these resales. Vor is a clinical-stage biopharma company developing telitacicept for autoimmune diseases, including a global Phase 3 trial in generalized myasthenia gravis.
Vor Biopharma Inc. filed Amendment No. 1 to its Form S-3, covering the resale by selling stockholders of up to 50,999,999 shares of common stock after effectiveness. The amendment adds Rule 473(b) language for automatic effectiveness 20 days after filing.
The shares consist of up to 16,000,000 issuable upon exercise of the RemeGen Warrant and up to 34,999,999 issuable upon exercise of PIPE Warrants; all figures reflect the 1-for-20 reverse stock split effected on September 18, 2025. The company will not receive proceeds from stockholder resales; it would receive cash only upon warrant exercises at $0.002 per share, totaling approximately $102,000 if fully exercised for cash. Examples of registered resale amounts include RemeGen Co., Ltd. 16,000,000 and RA Capital Healthcare Fund, L.P. 10,000,000. Shares outstanding were 6,853,907 as of September 18, 2025.